Genetic heterogeneity

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Retrieved on: 
火曜日, 12月 12, 2023
Constellation, Entrepreneurship, Hospital, Genetic code, MIT, CMC, CRISPR, JD, PASTE, Brigham and Women's Hospital, DNA, MD, Doctor of Philosophy, Therapy, Investment, HR, Polaris Partners, Novo Nordisk, Novartis, Polaris, Patent, MorphoSys, Cas9, ARCH, ARCH Venture Partners, Gene expression, Bruker, Genetic heterogeneity, Gene, Merck, PGI, Genome, Enzyme, Fujifilm, Patient, GV, Intellia Therapeutics

Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others

Key Points: 
  • Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others
    WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Tome Biosciences , Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI).
  • “PGI represents the maturation of editing technologies, breaking current barriers in genomic medicines discovery,” said Rahul Kakkar, MD, President and Chief Executive Officer.
  • “PGI is revolutionary in that we can finally reprogram the human genome with an elegance and efficiency previously unimaginable.
  • Tome has an exclusive license to the core PASTE technology, which includes granted US patent numbers 11,572,556, 11,827,881 and 11,834,658.

Mission Bio Announces Over 20 Presentations Demonstrating the Utility of Tapestri Across AML, Multiple Myeloma, and Lymphoma at the 2023 ASH Annual Meeting

Retrieved on: 
木曜日, 12月 7, 2023
Science, Other Science, Research, Oncology, General Health, Health, Genetics, Clinical Trials, Harvard University, Multiple myeloma, Bone marrow, Identification, Landscape, DNA, MIT, ASH, Clonal hematopoiesis, University of Navarra, MFC, Patient, PCR, Mission, Cell, Medicine, Differentiation, MD Anderson Cancer Center, B cell, MRD, Merck, Blood, CNV, Flow cytometry, Exposition, MD, Survival, AML, Doctor of Philosophy, Society, Translational medicine, Genetic heterogeneity, Hospital, Genentech, Pharmaceutical industry, Vaccine, Hematology, Franses Tapestry Archive

The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine.

Key Points: 
  • The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine.
  • Detected MRD-positive patients, which were deemed negative by MFC and PCR,
    Differentiated between clonal hematopoiesis (CH) clones and leukemic clones.
  • Data from other blood cancer studies will be presented by leading researchers in over 24 presentations leveraging Mission Bio’s Tapestri Platform, showcasing its broad application in hematology.
  • For a complete list of ASH presentations using Tapestri, please visit our website .

ORIEN Member Presentations at 2023 ASCO Demonstrate Unique Value of Aster Insights' Data

Retrieved on: 
火曜日, 5月 30, 2023
Roswell Park Comprehensive Cancer Center, Focused Ultrasound Foundation, Partnership, Doctor of Pharmacy, University, CRC, Aster, American Society of Clinical Oncology, Cancer, Development of the human body, Research, Roswell Park, RNA, Immunotherapy, Doctor of Philosophy, AVATAR, ASCO, DO, Patient, Data, Sequence, Annual general meeting, Inherit, Genetic heterogeneity, Listeria monocytogenes non-coding RNA, H. Lee Moffitt Cancer Center & Research Institute, WES, Health, Society, Compugen (company), WTS, Pharmaceutical industry, Medical imaging, Vaccine

TAMPA, Fla., May 30, 2023 /PRNewswire/ -- Aster Insights ("the Company"), the leading provider of technology-enabled data and analytics solutions for oncology discovery, today announced its participation as a research partner at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023 in Chicago, IL. An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® (ORIEN) AVATAR program. These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.

Key Points: 
  • An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® ( ORIEN ) AVATAR program.
  • These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.
  • "We are thrilled to be selected for these diverse presentations at ASCO that showcase the incredible work of ORIEN and Aster Insights," said Jill Kolesar, PharmD, Director of the Precision Medicine Center at the Markey Cancer Center and Chair of the ORIEN Executive Advisory Committee.
  • For more information about our ASCO presentations, please contact Aster Insights at: [email protected]

Baylor Genetics Announces Neuromuscular Disorders Panel

Retrieved on: 
月曜日, 5月 22, 2023
Baylor, Myopathy, NGS, Clinical trial, Prognosis, DSM-IV codes, Genetics, Whole genome sequencing, HIV disease progression rates, Genetic disorder, Patient, Physician, Medicine, Muscular dystrophy, WGS, Genetic testing, Genetic heterogeneity, Diagnosis, WES, Gene, Phenotype, Sequence, Genome, Disease, Vaccine, Medical device

In addition to panel testing, Baylor Genetics offers Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) -- two of the most comprehensive precision diagnostic tests -- backed by expert clinical support for actionable treatment guidance. WES is used to understand the cause of a patient's symptoms (phenotypes) or a disease, especially when faced with a nonspecific presentation that may not be captured in a single panel. It provides insights into all genes in the human body, ensuring a full understanding of most genetic disorders. WGS takes this a step further, providing insights into the entire human genome, including the regions between genes. This extensive analysis can significantly increase diagnostic yield over all other types of genetic testing, empowering physicians and patients to make the most informed decisions about future care, family planning, or clinical trial eligibility.

Key Points: 
  • HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of a Neuromuscular Disorders Panel (NGS Panel) .
  • Hereditary neuromuscular disorders can be difficult to accurately diagnose based on phenotype alone because of their inherent genetic heterogeneity.
  • Baylor Genetics’ Neuromuscular Disorders Panel assesses many genes based on a clinical indication to help clinicians and their patients achieve an accurate diagnosis sooner and have a better understanding of the prognosis and anticipated disease progression.
  • Visit our convenient online ordering portal to order the new Neuromuscular Disorders Panel today.

Global Schizophrenia Market to Reach $13 Billion by 2031 at a CAGR of 3.7% - ResearchAndMarkets.com

Retrieved on: 
火曜日, 11月 29, 2022
Pharmaceutical, Health, Mental Health, Growth, Psychosis, Compound annual growth rate, Clinical trial, Genetic heterogeneity, Patient, Government budget balance, Speech, CIAS, Hallucination, Memory, Therapy, Epidemiology, Disorder, Delusion, Poverty, Investment, Residential care, Pharmaceutical industry, Marketing, Retail, Schizophrenia

The schizophrenia market in the 7MM was valued at $9.0B in the 2021 baseline year.

Key Points: 
  • The schizophrenia market in the 7MM was valued at $9.0B in the 2021 baseline year.
  • The publisher anticipates that over the 10-year forecast period, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.7%, reaching $13.0B by 2031.
  • When will the late stage pipeline products launch, and how will they affect drug sales and the overall schizophrenia market in the 7MM?
  • The most promising candidates in Phase III and Phase IIb development are profiled
    Analysis of the current and future market competition in the global schizophrenia therapeutics market.

BostonGene Announces Publication in Cell Reports Revealing Spatial Heterogeneity in the Tumor Microenvironment of Multiregional Clear Cell Renal Cell Carcinoma Biopsies

Retrieved on: 
火曜日, 10月 4, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Washington University School of Medicine, TME, Cancer, Manuscript, Doctor of Philosophy, Sequence, CyTOF, WES, Research, Precision medicine, Economics, ITH, MD, Standard of care, Neoplasm, Cell Reports, RNA, Patient, Genetic heterogeneity, Biomarker, Tumor microenvironment, Washington University in St. Louis, RNA-Seq, Medical imaging, Medicine

Multiregional analyses revealed unexpected conservation of immune composition of the tumor microenvironment (TME) within each patient, with profound differences found among patients.

Key Points: 
  • Multiregional analyses revealed unexpected conservation of immune composition of the tumor microenvironment (TME) within each patient, with profound differences found among patients.
  • Further MxIF analysis showed striking spatial architectural heterogeneity among different regions of the same tumor, revealing the presence of diverse cellular neighborhoods.
  • BostonGene Tumor PortraitTM Testsreveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.
  • Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

Muscular Dystrophy Association Gathers Global Leaders at Annual Conference, the Largest Convening in the Field of Neuromuscular Disease Research & Care in the World

Retrieved on: 
水曜日, 2月 9, 2022
Molecule, Transfer, CRISPR, Industry, Duchenne muscular dystrophy, Muscular Dystrophy Association, Clinical trial, Multimedia, Gaylord Opryland Resort & Convention Center, Episcopal conference, Genetic heterogeneity, ALS, Science, Conference, Doctor of Philosophy, Convention center, Horizontal gene transfer, Session, Invention, Federation, 2021 Essex County Council election, Knowledge, Gene editing, Spinal muscular atrophy, Translation, CEO, Peripheral neuropathy, MDA, Duchenne, Chairperson, Environment, Neuromuscular disease, Telehealth, Drug development, CMT, SMA, Muscular dystrophy, IRIS, View, Degenerative disease, Amyotrophic lateral sclerosis, Charcot–Marie–Tooth disease, MPH, National Sexual Violence Resource Center, COVID-19, Pharmaceutical industry, Medical imaging, Industrial design, DMD, Gene, Research, MD

Day four of the conference will be devoted to oral presentations from selected abstracts submitted by scientific and clinical researchers.

Key Points: 
  • Day four of the conference will be devoted to oral presentations from selected abstracts submitted by scientific and clinical researchers.
  • "MDA's annual conference is the largest and most important convening on advances in understanding and treating neuromuscular diseases in the world.
  • "Our conference is the only one in the neuromuscular space that really combines everything from basic research to clinical care, treatment, and management."
  • For 70 years, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.

Veritas Intercontinental: Genetics makes it possible to identify cardiovascular genetic risk and prevent cardiac accidents such as those that have been in the news in recent days

Retrieved on: 
火曜日, 6月 22, 2021
Branches of biology, Biology, Human genetics, Genetics, DNA sequencing, Exome sequencing, Molecular biology, Exome, Medical genetics, Disease, Genetic heterogeneity, Genotype-first approach

This type of incidence and the possible fatal consequences result from an individual's genetic makeup.

Key Points: 
  • This type of incidence and the possible fatal consequences result from an individual's genetic makeup.
  • The analysis includes all genes recommended by the American Heart Association (AHA) analyzing 100 genes based on their relationship with different hereditary heart diseases.
  • myCardio allows a comprehensive approach to heart disease, with a new perspective that has been shown to be much more effective".
  • Whole exome sequencing (WES) is the most appropriate tool to address the genetic heterogeneity present in inherited cardiovascular disease.

Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Cystic Fibrosis

Retrieved on: 
火曜日, 2月 9, 2021
Medical specialties, Kidney diseases, Clinical medicine, Channelopathies, Rare diseases, Autosomal dominant disorders, Ciliopathy, Autosomal dominant polycystic kidney disease, Cystic fibrosis, Genetic disorder, Polycystic kidney disease, Genetic heterogeneity

These data support our current Phase 2 clinical trial for ELX-02 in cystic fibrosis patients with G542X nonsense alleles, for whom there are few, if any, treatment options available.

Key Points: 
  • These data support our current Phase 2 clinical trial for ELX-02 in cystic fibrosis patients with G542X nonsense alleles, for whom there are few, if any, treatment options available.
  • ELX-02 is in the early stages of clinical development focusing on cystic fibrosis.
  • Eloxx also has preclinical programs focused on kidney diseases including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.
  • Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control.